An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)’s share was trading ...
A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...
The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...
Heartseed Inc. and Novo Nordisk - in partnership since June 2021 - have announced that the first patient has been successfully dosed in a clinical study with HS-001, a cell therapy designed to ...
CVS Health and Walgreens have become the first two US pharmacy chains to agree a settlement worth nearly $10 billion to answer allegations they played a role in the opioid epidemic that has ...